Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(50.0%)
Early Phase 1
1(50.0%)
2Total
Phase 4(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03051204Completed

OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome

Role: collaborator

NCT03420976Early Phase 1Withdrawn

Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth

Role: collaborator

NCT01641341Phase 4Completed

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

Role: collaborator

All 3 trials loaded